Recon: FDA rejects Aquestive’s allergy therapy over packaging concerns; Novo’s CagriSema tops Wegovy in Phase 3 diabetes study

• New rule would force PBMs to disclose drug rebates and other fees (STAT)
• FDA rejects Aquestive's allergy drug over packaging issues (Endpoints)
• FDA opens submissions for PreCheck program to speed up US factory builds (Endpoints)
• Pharming’s immunodeficiency drug gets CRL for use in younger patients (Endpoints)
• Does America Still Know How to Spur Innovation? (Bloomberg)
• Top 10 most anticipated drug launches of 2026 (Fierce Pharma)

• Sanofi is reprimanded by a U.K. trade group for misleading claims about a Pfizer vaccine (STAT)
• European law changes mean drugmakers may have to grapple with generic competition sooner (Endpoints)
• China’s Pampered Cats Spur Weight-Loss Drug Application (Bloomberg)
• India to Spend $1.1 Billion to Make Biopharma Production Hub (Bloomberg)
• A Quality Tax for Foreign Drug Makers? The Links Between National Security, Trade Deals, and Drug Quality. (FDA Law Blog)

• Novo Nordisk's next-gen obesity drug outperforms Wegovy in late-stage diabetes trial (Reuters)
• Obesity market sales potential tightens as Novo and Lilly enter new era (Reuters)
• As male birth control gets closer to reality, men are lining up for clinical trials (STAT)
• As its immunology work draws attention, Sanofi also pushes forward in rare disease (STAT)
• GSK gives back rights to Wave Life Sciences' lead RNA editing program (Endpoints)
• SanegeneBio licenses RNAi candidate to Genentech for $200M upfront (Endpoints)
• Sanofi’s rare disease drug notches one win, one loss in a pair of Phase 3 trials (Endpoints)
• Even Tech Skeptics Can Cheer AI’s Promise in Decoding the 'Dark Genome' (Bloomberg)
• AstraZeneca Shares Start Trading in US After Listing Upgrade (Bloomberg)

• Boosting Your Brain With a Chip Carries a Price (Bloomberg)
• Lawsuit challenges ethylene oxide exemptions for device sterilizers (MedTech Dive)
• Grail files for FDA approval of multi-cancer early detection test (MedTech Dive)
• At INBRAIN’s 5-Year Mark, BCI Experts Confront The Promise, Perils Of Brain-Computer Interfaces (MedTech Insight)
• Thermo Fisher winds down Boston area plant (Fierce Pharma)

• France Lowers Limit for Toxin in Baby Formula, May Spark Recalls (Bloomberg)
• EU body's advice on toxin limit in baby formula prompts more recalls (Reuters)
• The food and beverage outlook for 2026 (Food Dive)

• Nine states challenge federal mandate that disabled people receive care in community (STAT)
• Newsom files a civil rights complaint against CMS’ Oz in latest feud with the Trump administration (STAT)
• The EPA just erased a century of public health progress (STAT)
• How much should psychedelics researchers disclose about their personal use? (STAT)